Neuland Laboratories Limited — Investor Meet, 16-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Neuland Labs delivered a robust Q4 & FY26. Q4 revenue surged to INR788.7 Cr (+134.9% YoY) with PAT at INR212.5 Cr, largely driven by commercial CMS projects. Full-year revenue hit INR2053.1 Cr (+37.1% YoY), achieving a 29.4% EBITDA margin. Management highlighted business lumpiness, suggesting evaluation over longer periods. Strategic investments include new peptide commercial facilities and an R&D center, aiming for long-term growth in complex programs. Despite short-term variability, the company expresses confidence in its pipeline and foundational capabilities for future value creation.